All stock lists
Aligos Therapeutics, Inc. (NASDAQ:ALGS)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
2.16-0.41 (-15.95%)
Market cap
$11.8M
Insider Score
Health Score
Analyst consensus
Listed since
Oct 16, 2020
Website
Insider Score
––Not scored
ALGS Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Weak
From ALGS’s reported statements · Q3 2026 (trailing 12 months)
Profitability0 / 20
Loses money on what it sells.
- Revenue
- $33.6M
- Net income
- -$66.3M
- Net margin
- -197.0%
Leverage9 / 20
A manageable debt load.
- Total debt
- $11.9M
- Cash
- $31.1M
- Debt / equity
- 1.05
Liquidity17 / 20
Comfortably covers what is due within a year.
- Current assets
- $34.7M
- Current liabilities
- $19.6M
- Current ratio
- 1.77
Cash generation0 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$68.4M
- Free cash flow
- -$68.7M
- FCF margin
- -204.1%
Dilution & runway0 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 10.5M
- Share growth (1y)
- 0.9%
- Cash runway
- 5 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
ALGS Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | $2.87 M | $27.78 M | $2.83 M | $169.00 K | $741.00 K | $965.00 K |
| Revenue Growth (YoY) | 287.18 % | 2778.55 % | 809.97 % | -73.13 % | -41.61 % | -9.05 % |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $257.00 K | $0.00 | $259.00 K |
| Gross Profit | $2.87 M | $27.78 M | $2.83 M | -$88.00 K | $741.00 K | $706.00 K |
| SG&A Expense | $5.87 M | $5.62 M | $6.41 M | $4.69 M | $5.17 M | $5.56 M |
| R&D Expense | $18.89 M | $24.05 M | $23.35 M | $17.04 M | $23.94 M | $13.98 M |
| Operating Expenses | $24.76 M | $29.67 M | $29.76 M | $21.73 M | $29.10 M | $19.27 M |
| Operating Income | -$21.89 M | -$1.89 M | -$26.93 M | -$21.81 M | -$28.36 M | -$18.57 M |
| Pretax Income | -$21.53 M | $1.31 M | -$22.72 M | -$19.85 M | -$31.48 M | -$15.68 M |
| Tax Provision | $326.00 K | $2.81 M | $317.00 K | $30.00 K | $56.00 K | $185.00 K |
| Net Income | -$21.86 M | -$1.50 M | -$23.04 M | -$19.88 M | -$31.54 M | -$15.86 M |
| EPS (Basic) | -$2.09 | -$0.14 | -$2.21 | -$1.91 | -$3.04 | -$1.53 |
| EPS (Diluted) | -$2.09 | -$0.14 | -$2.21 | -$1.91 | -$3.04 | -$1.53 |
| Shares Outstanding | 10.46 M | 10.43 M | 10.40 M | 10.38 M | 10.37 M | 10.35 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.